MALLINCKRODT MEDICAL BEGINS U.S. SALES OF ACS INTERVENTIONAL RADIOLOGY
This article was originally published in The Gray Sheet
Executive Summary
MALLINCKRODT MEDICAL BEGINS U.S. SALES OF ACS INTERVENTIONAL RADIOLOGY products under an exclusive world-wide distribution agreement announced by Mallinckrodt parent IMCERA on Feb. 12. Under the terms of the agreement, Mallinckrodt has rights to sell devices manufactured by the Peripheral Systems Group (PSG) of Lilly's Advanced Cardiovascular Systems, Inc. under its own label. The agreement includes PSG's line of percutaneous transluminal angioplasty (PTA) catheters, interventional guidewires, directional atherectomy systems, therapeutic infusion devices and related accessory products. Mallinckrodt has not yet begun distribution of the PSG products in international markets but expects to do so over the next 12 to 18 months. The arrangement also calls for Mallinckrodt Medical "to team with PSG's research and product development activities to ensure a continuing stream of new products." Mallinckrodt says that the PSG products will complement its current offerings in the radiology market, which include contrast media and diagnostic catheters. In fiscal 1992, Mallinckrodt's combined radiology/cardiology market generated $294 mil. in sales. Gary Curtis, general manager of PSG, commented that the distribution agreement will provide "a much larger sales organization than currently exists" for the PSG products and "one already held in high esteem by the radiologists." The exec added that PSG believes it can "significantly improve its market penetration with this alliance."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.